Conditional Probability of Survival in Patients With Newly Diagnosed Glioblastoma

Eitemau Tebyg

• Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide
  gan: Polley, Mei-Yin C., et al.
  Cyhoeddwyd: (2010)
• The Effect of Timing of Concurrent Chemoradiation in Patients With Newly Diagnosed Glioblastoma
  gan: Han, Seunggu J., et al.
  Cyhoeddwyd: (2015)
• Association of Diffusion and Anatomic Imaging Parameters with Survival for Patients with Newly Diagnosed Glioblastoma Participating in Two Different Clinical Trials()
  gan: Wen, Qiuting, et al.
  Cyhoeddwyd: (2015)
• Assessment of perfusion MRI-derived parameters in evaluating and predicting response to antiangiogenic therapy in patients with newly diagnosed glioblastoma
  gan: Essock-Burns, Emma, et al.
  Cyhoeddwyd: (2011)
• Survival analysis in patients with newly diagnosed glioblastoma using pre- and postradiotherapy MR spectroscopic imaging(†)
  gan: Li, Yan, et al.
  Cyhoeddwyd: (2013)